James Millis to Muromonab-CD3
This is a "connection" page, showing publications James Millis has written about Muromonab-CD3.
Connection Strength
0.450
-
Tacrolimus treatment of steroid-resistant rejection provides economic advantages compared with OKT3 therapy. Transplant Proc. 1997 Feb-Mar; 29(1-2):1549.
Score: 0.149
-
Treatment of steroid-resistant rejection with tacrolimus prior to OKT3 in liver transplant recipients. Transplant Proc. 1996 Apr; 28(2):1014.
Score: 0.140
-
OKT3 escalating dose regimens provide effective therapy for renal allograft rejection. Clin Transplant. 1996 Aug; 10(4):389-95.
Score: 0.036
-
Tacrolimus for primary treatment of steroid-resistant hepatic allograft rejection. Transplantation. 1996 May 15; 61(9):1365-9.
Score: 0.035
-
Lack of correlation between the magnitude of preservation injury and the incidence of acute rejection, need for OKT3, and conversion to FK506 in cyclosporine-treated primary liver allograft recipients. Transplantation. 1995 Sep 27; 60(6):554-8.
Score: 0.034
-
Liver transplantation in the first three months of life. Transplantation. 1998 Sep 15; 66(5):606-9.
Score: 0.010
-
Tacrolimus therapy for refractory acute renal allograft rejection: a 4-year experience with an aggressive approach. Transplant Proc. 1998 Jun; 30(4):1234-5.
Score: 0.010
-
Tacrolimus therapy for refractory renal allograft rejection: experience with steroid withdrawal. Transplant Proc. 1997 Feb-Mar; 29(1-2):307.
Score: 0.009
-
Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. Transplantation. 1996 Aug 15; 62(3):370-5.
Score: 0.009
-
Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506. Transplant Proc. 1996 Apr; 28(2):998-9.
Score: 0.009
-
Living-donor liver transplantation at UCLA. Am J Surg. 1995 May; 169(5):529-32.
Score: 0.008